Genetically modified organisms are the key step for innovative medicines. The innovative drugs in the 21st century will be in the majority of proteins, nucleic acids and their combinations. The critical issues in case of biopharmaceuticals are quality and reproducibility of production. These aspects are evident in biosimilars (generics) and protection of intellectual property rights.